Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $42.60.

COLL has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Piper Sandler reissued a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Truist Financial lifted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright increased their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of COLL. Janney Montgomery Scott LLC bought a new position in shares of Collegium Pharmaceutical in the first quarter worth $519,000. Texas Permanent School Fund Corp increased its stake in Collegium Pharmaceutical by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after acquiring an additional 369 shares during the last quarter. Gallacher Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the 1st quarter valued at about $223,000. LSV Asset Management boosted its position in shares of Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after acquiring an additional 248,751 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Collegium Pharmaceutical by 3.2% during the 1st quarter. Russell Investments Group Ltd. now owns 33,084 shares of the specialty pharmaceutical company’s stock valued at $1,284,000 after acquiring an additional 1,011 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $33.46 on Wednesday. The stock has a market cap of $1.08 billion, a P/E ratio of 12.97 and a beta of 0.95. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The company’s 50 day moving average price is $37.51 and its two-hundred day moving average price is $35.27. Collegium Pharmaceutical has a 52 week low of $21.40 and a 52 week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The business had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. During the same period last year, the company posted $1.13 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, equities analysts predict that Collegium Pharmaceutical will post 5.81 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.